NASHUA, N.H., April 19, 2022 (GLOBE NEWSWIRE) —

iCAD, Inc.

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will launch a new webinar series, ProFound Insights, ProFound Impact, which will highlight customer success stories throughout the year. The first event, “Why Kettering Health Traded out Previous AI Software for ProFound AI® Enterprise-Wide” will take place on Wednesday, April 27 from 1-2 pm EDT, featuring distinguished clinical and administrative experts from Kettering Health, a leading enterprise breast care provider with 14 breast centers across southwest Ohio. The event will be moderated by iCAD’s President and CEO, Stacey Stevens. Visit

this link

to register.

Featured panelists include:

• Sally Grady, Director of Kettering Health Breast Centers
• Meghan Musser, DO, Medical Director for Breast Imaging, Kettering Health

“ProFound AI is a game changer. Other AI technologies for DBT seem like smoke and mirrors when compared with ProFound AI. It is clearly the most advanced technology of its kind on the market, and we found it was going to fit well within the other components we offer in our screening program.”– Sally Grady, Director of Kettering Health Breast Centers

“ProFound AI has been something that we as radiologists have started to depend on and really want. Now that we have it available for all our patients coming in, it makes a big difference in our reading efficiency and in the care that we offer. Even the most skeptical of our breast radiologists are now on board with ProFound AI.” — Meghan Musser, DO, Medical Director for Breast Imaging, Kettering Health

About iCAD, Inc.



Headquartered in Nashua, NH, iCAD® is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit

www.icadmed.com

.

Forward-Looking Statements


Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contact:

Media Inquiries:

Jessica Burns, iCAD

+1-201-423-4492

[email protected]

Investor Inquiries:

iCAD Investor Relations


[email protected]